Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Robotic shavers for arthroscopic surgery, energy platforms that reduce tissue damage, and patient monitoring systems spanning five continents—all of these sit inside Conmed’s wide-ranging product portfolio. That diversity makes its regulatory disclosures dense. Whether you’re hunting for FDA clearance updates, forecasting disposable instrument demand, or tracking raw-material costs, Conmed annual report 10-K simplified insight is the starting point. Stock Titan curates every page so you can move straight to the sections that matter.
Our AI models read each Conmed quarterly earnings report 10-Q filing and surface shifts in segment revenue, gross margin and R&D spend before the conference call ends. Real-time alerts flag Conmed Form 4 insider transactions real-time, turning routine Conmed executive stock transactions Form 4 into actionable signals. Need governance details? The platform links directly to the Conmed proxy statement executive compensation tables, while our natural-language summaries translate the legalese. From warranty-accrual changes in an 8-K to new shelf registrations, Conmed SEC filings explained simply are only a click away.
Investors use these tools to:
- Compare orthopedics and endoscopic segment trajectories quarter over quarter through Conmed earnings report filing analysis.
- Monitor supply-chain disclosures and product-liability reserves when Conmed 8-K material events explained appear between quarters.
- Spot buying patterns by surgeons-turned-executives via Conmed insider trading Form 4 transactions.
Sitting on top of EDGAR’s feed, Stock Titan refreshes the moment a document drops, then delivers concise AI-powered summaries, red-line comparisons and keyword search across the entire archive. If you’ve ever wrestled with understanding Conmed SEC documents with AI, this page ends that struggle—empowering you to act quickly, ask sharper questions and keep your focus on surgical innovation, not paperwork.
CONMED Corporation reported that it plans to exit its gastroenterology product lines as part of a broader portfolio optimization strategy. The Company announced that this change includes ending its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent, effective January 1, 2026, and it expects to exit the rest of its gastroenterology product portfolio as well.
The update was communicated through a press release dated December 5, 2025, which is furnished as an exhibit to this report. The announcement signals a strategic refocus on other parts of CONMED’s business, but the filing does not provide financial details about the gastroenterology products being exited.
CONMED Corp (CNMD)$41.21 per share. Following this sale, the filing shows the officer beneficially owning 0 shares directly.
This is a routine Form 4 disclosure required by U.S. securities laws whenever company insiders buy or sell the company’s stock. It does not, by itself, explain the officer’s reasons for the transaction or signal any change in the company’s business operations.
CONMED Corporation’s Chief Information Officer, Richard Glaze, reported the settlement of restricted stock units in a Form 4 filing. On 11/20/2025, 375 RSUs were converted into shares of common stock at an exercise price of $0 per share, increasing his directly held common stock to 375 shares.
To cover taxes due on this vesting, 118 shares of common stock were disposed of at $40.63 per share, leaving 257 shares of common stock held directly after the withholding. Following the transaction, 750 RSUs remain outstanding, each representing a contingent right to receive one share of CONMED common stock.
CONMED Corporation (CNMD) reported a planned sale of company stock by an affiliate under Rule 144. The notice covers the proposed sale of 257 shares of CNMD common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $10,590.97. The filing states that the issuer had 30,967,954 shares outstanding of the same class at the time referenced.
The 257 shares being sold were acquired on 11/20/2025 through a restricted stock vesting transaction from the issuer, with the consideration classified as compensation. The person for whose account the securities are to be sold must represent that they are not aware of any undisclosed material adverse information about CONMED’s current or prospective operations before proceeding with the sale.
Capital Research Global Investors filed Amendment No. 3 to Schedule 13G on CONMED Corp. (CNMD), reporting beneficial ownership of 1,032,733 shares of common stock, representing 3.3% of the class.
The filer reports sole voting power over 1,032,733 shares and sole dispositive power over 1,032,733 shares, with no shared power. The filing identifies the reporting person type as IA (investment adviser). The ownership is certified as acquired and held in the ordinary course and not for the purpose of changing or influencing control.
CRGI notes its 3.3% is based on 30,954,963 shares believed to be outstanding. The date of event requiring the filing is 09/30/2025.
CONMED Corp (CNMD): Insider transaction reported. The company’s Executive Vice President & CFO reported selling 3,500 shares of common stock at $43 on 11/06/2025. Following this open‑market sale, the reporting person beneficially owns 1,836 shares, held directly. The filing indicates the report was made by one reporting person.
CONMED (CNMD) reported Q3 2025 results. Net sales were $337.9 million, up 6.7% year over year, led by General Surgery and Orthopedic Surgery. Diluted EPS was $0.09 as net income fell to $2.9 million.
Gross margin declined to 49.2% (down 730 bps). The quarter included $19.7 million of write-offs tied to canceled product lines and discontinued SKUs, $3.7 million of consulting costs in cost of sales, and tariff impacts. Selling and administrative expense rose to $140.3 million, reflecting $5.5 million in operational optimization consulting, expense from contingent consideration fair value changes, and advisory services earlier in the year.
Year to date, operating cash flow was $124.4 million. Cash was $38.9 million and total long‑term debt was $853.0 million, including $60.0 million outstanding under the term loan and $800.0 million of 2.250% convertible notes due 2027. Interest expense decreased to $7.6 million. The company noted DOJ closed its voluntary disclosure matter with no action.
CONMED (CNMD) received a Form 144 notice indicating a planned sale of restricted securities by an affiliate. The filer intends to sell 3,500 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $150,500.00. The shares are listed on the NYSE, with an approximate sale date of 11/06/2025.
The securities were acquired on 10/31/2025 via restricted stock vesting from the issuer as compensation. As context, shares outstanding were 30,954,963. In the prior three months, the seller reported a sale of 598 shares on 08/07/2025 for $31,365.10.
Form 144 is a notice of proposed sale and does not involve proceeds to the company.
CONMED Corporation furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, dated November 5, 2025.
The company states the information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act filings unless specifically referenced.
CONMED (CNMD) disclosed an insider equity transaction. On 11/04/2025, the General Counsel & Corporate Secretary converted 4,000 RSUs into common stock (code M) at $0 and satisfied taxes by withholding 1,114 shares at $45.71 per share (code F). After these transactions, 2,886 common shares were owned directly. The RSUs are under the 2018 Long‑Term Incentive Plan and vest over two years, 50% after year 1 and 50% after year 2.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
